Transcriptomic biomarkers for individual risk assessment in new onset heart failure

Abstract

A novel transcriptomic biomarker for prognosis in heart failure has a direct clinical application in prediction of prognosis in new onset heart failure, heart disease, heart disorders and associated heart conditions. This approach should improve individualization of cardiac care and help identify patients at highest risk for circulatory collapse within the first years of presentation with heart failure.

1 . A molecular composition comprising biomarker molecules: 232669_at (Hypoxia inducible factor 3, alpha subunit), 214951_at (solute carrier family 26, member 10), 243482_at (Epidermal growth factor receptor pathway substrate 15-like 1), 226210_s_at (maternally expressed 3), 232159_at (Epidermal growth factor receptor pathway substrate 15-like 1), 233026_s_at (PDZ domain containing), 211996_s_at (KIAA0220-like protein hypothetical gene LOC 283846), 243774_at (mucin 20, cell surface associated), 242551_at (Chromosome 18 open reading frame), 244548_at (Rho GTPase activating protein 26), 244208_at (Checkpoint suppressor 1), 239984_at (Sodium channel, voltage-gated, type VII, alpha), 230683_at (cDNA:FLJ20892 fis, clone ADKA03430), 214869_at (apolipoprotein L, 6), 241597_at (Arginine-glutamic acid dipeptide (RE) repeats), 235887_at (5 mg-6 homolog, nonsense mediated mRNA decay factor ( C. elegans )), 229957_at (transmembrane protein 91), 223546_x_at (LUC7L-like ( S. cerevisiae )), 239567_at (Rho GTPase activating protein 10), 242194_at (Cullin 4A), 1558525_at (hypothetical protein LOC283901), 227178_at (CUG triplet repeat, RNA binding protein 2), 228198_s_at (Mitochondrial ribosomal protein S9), 202379_s_at (natural killer-tumor recognition sequence), 224260_at (cDNA clone), 238643_at (Neuroblastoma, suppression of tumorigenicity 1), 232253_at (RAD50 homolog ( S. cerevisiae )), 227968_at (Parkinson disease 7 domain containing 1), 233197_at (kelch-like 9 ( Drosophila )), 244512_at (transcribed locus strongly similar to XP — 0010813421), 233443_at (hypothetical protein LOC389362), 231275_at (FLJ42875 protein), 226419_s_at (hypothetical protein LOC64546), 201221_s_at small nuclear ribonucleoprotein 70 kDa polypeptide), 209354_at (tumor necrosis factor receptor family member 14), 226571_s_at (protein tyrosine phosphatase receptor type, S), 220728_at (EST), 203071_at (sema domain, immunoglobulin domain (Ig), short basic domain), 213946_s_at obscurin-like 1, similar to titin isoform N2-B), 201394_s_at (RNA binding motif protein 5), 203748_x_at (RNA binding motif, single stranded interacting protein 1), 223147_s_at (WD repeat domain 33), 213773_x_at (NOL/NOP2/Sun domain family, member 5), 1560049_at CUG triplet repeat, RNA binding protein 2), 243974_at (cDNA clone IMAGE:4821815), 201510_at E74-like factor 3 (ets domain transcription factor, epithelial specific), complementary sequences, fragments, alleles, variants, derivatives and/or gene products thereof. 
   
   
       2 . The molecular composition of  claim 1 , wherein the biomarker comprises markers: 232669_at (Hypoxia inducible factor 3, alpha subunit), 214951_at (solute carrier family 26, member 10), 243482_at (Epidermal growth factor receptor pathway substrate 15-like 1), 226210_s_at (maternally expressed 3), 232159_at (Epidermal growth factor receptor pathway substrate 15-like 1), 233026_s_at (PDZ domain containing), 211996_s_at (KIAA0220-like protein hypothetical gene LOC 283846), 243774_at (mucin 20, cell surface associated), 242551_at (Chromosome 18 open reading frame), 244548_at (Rho GTPase activating protein 26), 244208_at (Checkpoint suppressor 1), 239984_at (Sodium channel, voltage-gated, type VII, alpha), 230683_at (cDNA:FLJ20892 fis, clone ADKA03430), 214869_at (apolipoprotein L, 6), 241597_at (Arginine-glutamic acid dipeptide (RE) repeats), 235887_at (5 mg-6 homolog, nonsense mediated mRNA decay factor ( C. elegans )), 229957_at (transmembrane protein 91), 223546_x_at (LUC7L-like ( S. cerevisiae )), 239567_at (Rho GTPase activating protein 10), 242194_at (Cullin 4A), 1558525_at (hypothetical protein LOC283901), 227178_at (CUG triplet repeat, RNA binding protein 2), 228198_s_at (Mitochondrial ribosomal protein S9), 202379_s_at (natural killer-tumor recognition sequence), 224260_at (cDNA clone), 238643_at (Neuroblastoma, suppression of tumorigenicity 1), 232253_at (RAD50 homolog ( S. cerevisiae )), 227968_at (Parkinson disease 7 domain containing 1), 233197_at (kelch-like 9 ( Drosophila )), 244512_at (transcribed locus strongly similar to XP — 0010813421), 233443_at (hypothetical protein LOC389362), 231275_at (FLJ42875 protein), 226419_s_at (hypothetical protein LOC64546), 201221_s_at small nuclear ribonucleoprotein 70 kDa polypeptide), 209354_at (tumor necrosis factor receptor family member 14), 226571_s_at (protein tyrosine phosphatase receptor type, S), 220728_at (EST), 203071_at (sema domain, immunoglobulin domain (Ig), short basic domain), 213946_s_at obscurin-like 1, similar to titin isoform N2-B), 201394_s_at (RNA binding motif protein 5), 203748_x_at (RNA binding motif, single stranded interacting protein 1), 223147_s_at (WD repeat domain 33), 213773_x_at (NOL/NOP2/Sun domain family, member 5), 1560049_at CUG triplet repeat, RNA binding protein 2), 243974_at (cDNA clone IMAGE:4821815); and, 201510_at E74-like factor 3 (ets domain transcription factor, epithelial specific). 
   
   
       3 . The molecular composition of  claim 1 , wherein detection in a cell or patient of the gene sequences, complementary sequences, fragments, alleles, variants, derivatives and/or gene products thereof, is prognostic of a desirable clinical prognosis in heart failure. 
   
   
       4 . The molecular composition of  claim 1 , wherein the gene sequences, complementary sequences, fragments, alleles, variants, derivatives and/or gene products thereof, are modulated and/or over-expressed at levels by at least 1% to a 100% or more in a cell or patient as compared to levels in a normal cell or normal subject. 
   
   
       5 . The molecular composition of  claim 1 , wherein the gene sequences, complementary sequences, fragments, alleles, variants, derivatives and/or gene products thereof, are modulated and/or over-expressed by about 50% in a cell or a patient as compared to levels in a normal cell or normal subject. 
   
   
       6 . The molecular composition of  claim 1 , wherein the gene sequences, complementary sequences, fragments, alleles, variants, derivatives and/or gene products thereof, are modulated and/or over-expressed by about 75% in a cell or a patient as compared to levels in a normal cell or normal subject. 
   
   
       7 . The molecular composition of  claim 1 , wherein at least ten gene sequences are prognostic in individual risk assessment in a patient for onset of heart failure. 
   
   
       8 . The molecular composition of  claim 1 , wherein a plurality of gene sequences are prognostic in individual risk assessment in a patient for onset of heart failure. 
   
   
       9 . A biomarker (TBB) for predicting a prognosis of heart failure, comprising biomolecules comprising: 232669_at (Hypoxia inducible factor 3, alpha subunit), 214951_at (solute carrier family 26, member 10), 243482_at (Epidermal growth factor receptor pathway substrate 15-like 1), 226210_s_at (maternally expressed 3), 232159_at (Epidermal growth factor receptor pathway substrate 15-like 1), 233026_s_at (PDZ domain containing), 211996_s_at (KIAA0220-like protein hypothetical gene LOC 283846), 243774_at (mucin 20, cell surface associated), 242551_at (Chromosome 18 open reading frame), 244548_at (Rho GTPase activating protein 26), 244208_at (Checkpoint suppressor 1), 239984_at (Sodium channel, voltage-gated, type VII, alpha), 230683_at (cDNA:FLJ20892 fis, clone ADKA03430), 214869_at (apolipoprotein L, 6), 241597_at (Arginine-glutamic acid dipeptide (RE) repeats), 235887_at (5 mg-6 homolog, nonsense mediated mRNA decay factor ( C. elegans )), 229957_at (transmembrane protein 91), 223546_x_at (LUC7L-like ( S. cerevisiae )), 239567_at (Rho GTPase activating protein 10), 242194_at (Cullin 4A), 1558525_at (hypothetical protein LOC283901), 227178_at (CUG triplet repeat, RNA binding protein 2), 228198_s_at (Mitochondrial ribosomal protein S9), 202379_s_at (natural killer-tumor recognition sequence), 224260_at (cDNA clone), 238643_at (Neuroblastoma, suppression of tumorigenicity 1), 232253_at (RAD50 homolog ( S. cerevisiae )), 227968_at (Parkinson disease 7 domain containing 1), 233197_at (kelch-like 9 ( Drosophila )), 244512_at (transcribed locus strongly similar to XP — 0010813421), 233443_at (hypothetical protein LOC389362), 231275_at (FLJ42875 protein), 226419_s_at (hypothetical protein LOC64546), 201221_s_at small nuclear ribonucleoprotein 70 kDa polypeptide), 209354_at (tumor necrosis factor receptor family member 14), 226571_s_at (protein tyrosine phosphatase receptor type, S), 220728_at (EST), 203071_at (sema domain, immunoglobulin domain (Ig), short basic domain), 213946_s_at obscurin-like 1, similar to titin isoform N2-B), 201394_s_at (RNA binding motif protein 5), 203748_x_at (RNA binding motif, single stranded interacting protein 1), 223147_s_at (WD repeat domain 33), 213773_x_at (NOL/NOP2/Sun domain family, member 5), 1560049_at CUG triplet repeat, RNA binding protein 2), 243974_at (cDNA clone IMAGE:4821815), 201510_at E74-like factor 3 (ets domain transcription factor, epithelial specific), complementary sequences, fragments, alleles, variants, derivatives and/or gene products thereof. 
   
   
       10 . The biomarker (TBB) of  claim 9 , comprising biomolecules comprising: 232669_at (Hypoxia inducible factor 3, alpha subunit), 214951_at (solute carrier family 26, member 10), 243482_at (Epidermal growth factor receptor pathway substrate 15-like 1), 226210_s_at (maternally expressed 3), 232159_at (Epidermal growth factor receptor pathway substrate 15-like 1), 233026_s_at (PDZ domain containing), 211996_s_at (KIAA0220-like protein hypothetical gene LOC 283846), 243774_at (mucin 20, cell surface associated), 242551_at (Chromosome 18 open reading frame), 244548_at (Rho GTPase activating protein 26), 244208_at (Checkpoint suppressor 1), 239984_at (Sodium channel, voltage-gated, type VII, alpha), 230683_at (cDNA:FLJ20892 fis, clone ADKA03430), 214869_at (apolipoprotein L, 6), 241597_at (Arginine-glutamic acid dipeptide (RE) repeats), 235887_at (5 mg-6 homolog, nonsense mediated mRNA decay factor ( C. elegans )), 229957_at (transmembrane protein 91), 223546_x_at (LUC7L-like ( S. cerevisiae )), 239567_at (Rho GTPase activating protein 10), 242194_at (Cullin 4A), 1558525_at (hypothetical protein LOC283901), 227178_at (CUG triplet repeat, RNA binding protein 2), 228198_s_at (Mitochondrial ribosomal protein S9), 202379_s_at (natural killer-tumor recognition sequence), 224260_at (cDNA clone), 238643_at (Neuroblastoma, suppression of tumorigenicity 1), 232253_at (RAD50 homolog ( S. cerevisiae )), 227968_at (Parkinson disease 7 domain containing 1), 233197_at (kelch-like 9 ( Drosophila )), 244512_at (transcribed locus strongly similar to XP — 0010813421), 233443_at (hypothetical protein LOC389362), 231275_at (FLJ42875 protein), 226419_s_at (hypothetical protein LOC64546), 201221_s_at small nuclear ribonucleoprotein 70 kDa polypeptide), 209354_at (tumor necrosis factor receptor family member 14), 226571_s_at (protein tyrosine phosphatase receptor type, S), 220728_at (EST), 203071_at (sema domain, immunoglobulin domain (Ig), short basic domain), 213946_s_at obscurin-like 1, similar to titin isoform N2-B), 201394_s_at (RNA binding motif protein 5), 203748_x_at (RNA binding motif, single stranded interacting protein 1), 223147_s_at (WD repeat domain 33), 213773_x_at (NOL/NOP2/Sun domain family, member 5), 1560049_at CUG triplet repeat, RNA binding protein 2), 243974_at (cDNA clone IMAGE:4821815) and, 201510_at E74-like factor 3 (ets domain transcription factor, epithelial specific). 
   
   
       11 . The biomarker of  claim 9 , wherein the gene sequences, complementary sequences, fragments, alleles, variants, derivatives and/or gene products thereof, are modulated and/or over-expressed at levels by at least 1% to a 100% or more in a cell or patient as compared to levels in a normal cell or normal subject. 
   
   
       12 . The biomarker of  claim 9 , wherein the gene sequences, complementary sequences, fragments, alleles, variants, derivatives and/or gene products thereof, are modulated and/or over-expressed by about 50% in a cell or a patient as compared to levels in a normal cell or normal subject. 
   
   
       13 . The biomarker of  claim 9 , wherein the gene sequences, complementary sequences, fragments, alleles, variants, derivatives and/or gene products thereof, are modulated and/or over-expressed by about 75% in a cell or a patient as compared to levels in a normal cell or normal subject. 
   
   
       14 . A biomarker (TBB) for predicting a prognosis of heart failure, comprising biomolecules consisting of: 232669_at (Hypoxia inducible factor 3, alpha subunit), 214951_at (solute carrier family 26, member 10), 243482_at (Epidermal growth factor receptor pathway substrate 15-like 1), 226210_s_at (maternally expressed 3), 232159_at (Epidermal growth factor receptor pathway substrate 15-like 1), 233026_s_at (PDZ domain containing), 211996_s_at (KIAA0220-like protein hypothetical gene LOC 283846), 243774_at (mucin 20, cell surface associated), 242551_at (Chromosome 18 open reading frame), 244548_at (Rho GTPase activating protein 26), 244208_at (Checkpoint suppressor 1), 239984_at (Sodium channel, voltage-gated, type VII, alpha), 230683_at (cDNA:FLJ20892 fis, clone ADKA03430), 214869_at (apolipoprotein L, 6), 241597_at (Arginine-glutamic acid dipeptide (RE) repeats), 235887_at (5 mg-6 homolog, nonsense mediated mRNA decay factor ( C. elegans )), 229957_at (transmembrane protein 91), 223546_x_at (LUC7L-like ( S. cerevisiae )), 239567_at (Rho GTPase activating protein 10), 242194_at (Cullin 4A), 1558525_at (hypothetical protein LOC283901), 227178_at (CUG triplet repeat, RNA binding protein 2), 228198_s_at (Mitochondrial ribosomal protein S9), 202379_s_at (natural killer-tumor recognition sequence), 224260_at (cDNA clone), 238643_at (Neuroblastoma, suppression of tumorigenicity 1), 232253_at (RAD50 homolog ( S. cerevisiae )), 227968_at (Parkinson disease 7 domain containing 1), 233197_at (kelch-like 9 ( Drosophila )), 244512_at (transcribed locus strongly similar to XP — 0010813421), 233443_at (hypothetical protein LOC389362), 231275_at (FLJ42875 protein), 226419_s_at (hypothetical protein LOC64546), 201221_s_at small nuclear ribonucleoprotein 70 kDa polypeptide), 209354_at (tumor necrosis factor receptor family member 14), 226571_s_at (protein tyrosine phosphatase receptor type, S), 220728_at (EST), 203071_at (sema domain, immunoglobulin domain (Ig), short basic domain), 213946_s_at obscurin-like 1, similar to titin isoform N2-B), 201394_s_at (RNA binding motif protein 5), 203748_x_at (RNA binding motif, single stranded interacting protein 1), 223147_s_at (WD repeat domain 33), 213773_x_at (NOL/NOP2/Sun domain family, member 5), 1560049_at CUG triplet repeat, RNA binding protein 2), 243974_at (cDNA clone IMAGE:4821815), 201510_at E74-like factor 3 (ets domain transcription factor, epithelial specific), complementary sequences, fragments, alleles, variants, derivatives and/or gene products thereof. 
   
   
       15 . A biomarker (TBB) for predicting a prognosis of heart failure, comprising biomolecules consisting of: 232669_at (Hypoxia inducible factor 3, alpha subunit), 214951_at (solute carrier family 26, member 10), 243482_at (Epidermal growth factor receptor pathway substrate 15-like 1), 226210_s_at (maternally expressed 3), 232159_at (Epidermal growth factor receptor pathway substrate 15-like 1), 233026_s_at (PDZ domain containing), 211996_s_at (KIAA0220-like protein hypothetical gene LOC 283846), 243774_at (mucin 20, cell surface associated), 242551_at (Chromosome 18 open reading frame), 244548_at (Rho GTPase activating protein 26), 244208_at (Checkpoint suppressor 1), 239984_at (Sodium channel, voltage-gated, type VII, alpha), 230683_at (cDNA:FLJ20892 fis, clone ADKA03430), 214869_at (apolipoprotein L, 6), 241597_at (Arginine-glutamic acid dipeptide (RE) repeats), 235887_at (5 mg-6 homolog, nonsense mediated mRNA decay factor ( C. elegans )), 229957_at (transmembrane protein 91), 223546_x_at (LUC7L-like ( S. cerevisiae )), 239567_at (Rho GTPase activating protein 10), 242194_at (Cullin 4A), 1558525_at (hypothetical protein LOC283901), 227178_at (CUG triplet repeat, RNA binding protein 2), 228198_s_at (Mitochondrial ribosomal protein S9), 202379_s_at (natural killer-tumor recognition sequence), 224260_at (cDNA clone), 238643_at (Neuroblastoma, suppression of tumorigenicity 1), 232253_at (RAD50 homolog ( S. cerevisiae )), 227968_at (Parkinson disease 7 domain containing 1), 233197_at (kelch-like 9 ( Drosophila )), 244512_at (transcribed locus strongly similar to XP — 0010813421), 233443_at (hypothetical protein LOC389362), 231275_at (FLJ42875 protein), 226419_s_at (hypothetical protein LOC64546), 201221_s_at small nuclear ribonucleoprotein 70 kDa polypeptide), 209354_at (tumor necrosis factor receptor family member 14), 226571_s_at (protein tyrosine phosphatase receptor type, S), 220728_at (EST), 203071_at (sema domain, immunoglobulin domain (Ig), short basic domain), 213946_s_at obscurin-like 1, similar to titin isoform N2-B), 201394_s_at (RNA binding motif protein 5), 203748_x_at (RNA binding motif, single stranded interacting protein 1), 223147_s_at (WD repeat domain 33), 213773_x_at (NOL/NOP2/Sun domain family, member 5), 1560049_at CUG triplet repeat, RNA binding protein 2), 243974_at (cDNA clone IMAGE:4821815), 201510_at E74-like factor 3 (ets domain transcription factor, epithelial specific), or combinations thereof. 
   
   
       16 . An antibody or aptamer specific for each biomolecule comprising: 232669_at (Hypoxia inducible factor 3, alpha subunit), 214951_at (solute carrier family 26, member 10), 243482_at (Epidermal growth factor receptor pathway substrate 15-like 1), 226210_s_at (maternally expressed 3), 232159_at (Epidermal growth factor receptor pathway substrate 15-like 1), 233026_s_at (PDZ domain containing), 211996_s_at (KIAA0220-like protein hypothetical gene LOC 283846), 243774_at (mucin 20, cell surface associated), 242551_at (Chromosome 18 open reading frame), 244548_at (Rho GTPase activating protein 26), 244208_at (Checkpoint suppressor 1), 239984_at (Sodium channel, voltage-gated, type VII, alpha), 230683_at (cDNA:FLJ20892 fis, clone ADKA03430), 214869_at (apolipoprotein L, 6), 241597_at (Arginine-glutamic acid dipeptide (RE) repeats), 235887_at (5 mg-6 homolog, nonsense mediated mRNA decay factor ( C. elegans )), 229957_at (transmembrane protein 91), 223546_x_at (LUC7L-like ( S. cerevisiae )), 239567_at (Rho GTPase activating protein 10), 242194_at (Cullin 4A), 1558525_at (hypothetical protein LOC283901), 227178_at (CUG triplet repeat, RNA binding protein 2), 228198_s_at (Mitochondrial ribosomal protein S9), 202379_s_at (natural killer-tumor recognition sequence), 224260_at (cDNA clone), 238643_at (Neuroblastoma, suppression of tumorigenicity 1), 232253_at (RAD50 homolog ( S. cerevisiae )), 227968_at (Parkinson disease 7 domain containing 1), 233197_at (kelch-like 9 ( Drosophila )), 244512_at (transcribed locus strongly similar to XP — 0010813421), 233443_at (hypothetical protein LOC389362), 231275_at (FLJ42875 protein), 226419_s_at (hypothetical protein LOC64546), 201221_s_at small nuclear ribonucleoprotein 70 kDa polypeptide), 209354_at (tumor necrosis factor receptor family member 14), 226571_s_at (protein tyrosine phosphatase receptor type, S), 220728_at (EST), 203071_at (sema domain, immunoglobulin domain (Ig), short basic domain), 213946_s_at obscurin-like 1, similar to titin isoform N2-B), 201394_s_at (RNA binding motif protein 5), 203748_x_at (RNA binding motif, single stranded interacting protein 1), 223147_s_at (WD repeat domain 33), 213773_x_at (NOL/NOP2/Sun domain family, member 5), 1560049_at CUG triplet repeat, RNA binding protein 2), 243974_at (cDNA clone IMAGE:4821815), 201510_at E74-like factor 3 (ets domain transcription factor, epithelial specific), complementary sequences, fragments, alleles, variants, derivatives and/or gene products thereof. 
   
   
       17 . A biochip comprising nucleic acid sequences: 232669_at (Hypoxia inducible factor 3, alpha subunit), 214951_at (solute carrier family 26, member 10), 243482_at (Epidermal growth factor receptor pathway substrate 15-like 1), 226210_s_at (maternally expressed 3), 232159_at (Epidermal growth factor receptor pathway substrate 15-like 1), 233026_s_at (PDZ domain containing), 211996_s_at (KIAA0220-like protein hypothetical gene LOC 283846), 243774_at (mucin 20, cell surface associated), 242551_at (Chromosome 18 open reading frame), 244548_at (Rho GTPase activating protein 26), 244208_at (Checkpoint suppressor 1), 239984_at (Sodium channel, voltage-gated, type VII, alpha), 230683_at (cDNA:FLJ20892 fis, clone ADKA03430), 214869_at (apolipoprotein L, 6), 241597_at (Arginine-glutamic acid dipeptide (RE) repeats), 235887_at (5 mg-6 homolog, nonsense mediated mRNA decay factor ( C. elegans )), 229957_at (transmembrane protein 91), 223546_x_at (LUC7L-like ( S. cerevisiae )), 239567_at (Rho GTPase activating protein 10), 242194_at (Cullin 4A), 1558525_at (hypothetical protein LOC283901), 227178_at (CUG triplet repeat, RNA binding protein 2), 228198_s_at (Mitochondrial ribosomal protein S9), 202379_s_at (natural killer-tumor recognition sequence), 224260_at (cDNA clone), 238643_at (Neuroblastoma, suppression of tumorigenicity 1), 232253_at (RAD50 homolog ( S. cerevisiae )), 227968_at (Parkinson disease 7 domain containing 1), 233197_at (kelch-like 9 ( Drosophila )), 244512_at (transcribed locus strongly similar to XP — 0010813421), 233443_at (hypothetical protein LOC389362), 231275_at (FLJ42875 protein), 226419_s_at (hypothetical protein LOC64546), 201221_s_at small nuclear ribonucleoprotein 70 kDa polypeptide), 209354_at (tumor necrosis factor receptor family member 14), 226571_s_at (protein tyrosine phosphatase receptor type, S), 220728_at (EST), 203071_at (sema domain, immunoglobulin domain (Ig), short basic domain), 213946_s_at obscurin-like 1, similar to titin isoform N2-B), 201394_s_at (RNA binding motif protein 5), 203748_x_at (RNA binding motif, single stranded interacting protein 1), 223147_s_at (WD repeat domain 33), 213773_x_at (NOL/NOP2/Sun domain family, member 5), 1560049_at CUG triplet repeat, RNA binding protein 2), 243974_at (cDNA clone IMAGE:4821815), 201510_at E74-like factor 3 (ets domain transcription factor, epithelial specific), complementary sequences, fragments, alleles, variants, derivatives and/or gene products thereof. 
   
   
       18 . The biochip of  claim 17 , wherein the biochip comprises at least ten nucleic acid sequences, complementary sequences, fragments, alleles, variants, derivatives and/or gene products thereof. 
   
   
       19 . A method of assessing identifying and distinguishing between patients at a high risk of heart disease and patients with a good prognosis for recovery comprising:
 quantifying in a biological sample from a patient a molecular signature comprising a transcriptomic based biomarker (TBB): 232669_at (Hypoxia inducible factor 3, alpha subunit), 214951_at (solute carrier family 26, member 10), 243482_at (Epidermal growth factor receptor pathway substrate 15-like 1), 226210_s_at (maternally expressed 3), 232159_at (Epidermal growth factor receptor pathway substrate 15-like 1), 233026_s_at (PDZ domain containing), 211996_s_at (KIAA0220-like protein hypothetical gene LOC 283846), 243774_at (mucin 20, cell surface associated), 242551_at (Chromosome 18 open reading frame), 244548_at (Rho GTPase activating protein 26), 244208_at (Checkpoint suppressor 1), 239984_at (Sodium channel, voltage-gated, type VII, alpha), 230683_at (cDNA:FLJ20892 fis, clone ADKA03430), 214869_at (apolipoprotein L, 6), 241597_at (Arginine-glutamic acid dipeptide (RE) repeats), 235887_at (5 mg-6 homolog, nonsense mediated mRNA decay factor ( C. elegans )), 229957_at (transmembrane protein 91), 223546_x_at (LUC7L-like ( S. cerevisiae )), 239567_at (Rho GTPase activating protein 10), 242194_at (Cullin 4A), 1558525_at (hypothetical protein LOC283901), 227178_at (CUG triplet repeat, RNA binding protein 2), 228198_s_at (Mitochondrial ribosomal protein S9), 202379_s_at (natural killer-tumor recognition sequence), 224260_at (cDNA clone), 238643_at (Neuroblastoma, suppression of tumorigenicity 1), 232253_at (RAD50 homolog ( S. cerevisiae )), 227968_at (Parkinson disease 7 domain containing 1), 233197_at (kelch-like 9 ( Drosophila )), 244512_at (transcribed locus strongly similar to XP — 0010813421), 233443_at (hypothetical protein LOC389362), 231275_at (FLJ42875 protein), 226419_s_at (hypothetical protein LOC64546), 201221_s_at small nuclear ribonucleoprotein 70 kDa polypeptide), 209354_at (tumor necrosis factor receptor family member 14), 226571_s_at (protein tyrosine phosphatase receptor type, S), 220728_at (EST), 203071_at (sema domain, immunoglobulin domain (Ig), short basic domain), 213946_s_at obscurin-like 1, similar to titin isoform N2-B), 201394_s_at (RNA binding motif protein 5), 203748_x_at (RNA binding motif, single stranded interacting protein 1), 223147_s_at (WD repeat domain 33), 213773_x_at (NOL/NOP2/Sun domain family, member 5), 1560049_at CUG triplet repeat, RNA binding protein 2), 243974_at (cDNA clone IMAGE:4821815), 201510_at E74-like factor 3 (ets domain transcription factor, epithelial specific), complementary sequences, fragments, alleles, variants, derivatives and/or gene products thereof;   assessing the probability of identification of each component gene in each sample;   assigning each to a class; and,   differentiating between idiopathic cardiomyopathy and myocarditis.   
   
   
       20 . The method of  claim 19 , wherein the biomarker is identified from a patient by isolating nucleic acids obtained from a biological sample. 
   
   
       21 . The method of  claim 20 , wherein the nucleic acids are hybridized to the biochip and raw intensity values from microarray hybridization are normalized and phenotype specific differences in gene expression are identified. 
   
   
       22 . The method of  claim 21 , wherein the differences in gene expression are identified by significance analysis of microarrays, wherein significance is defined with a q-value and multiple comparisons comprise an adjusted p-value. 
   
   
       23 . The method of  claim 21 , wherein the phenotype specificity is identified by creating a classifier in a training set comprising about 66% of data obtained, with subsequent validation in a test set comprising about 33% of data obtained and defining a phenotype specific nearest shrunken centroid for classification. 
   
   
       24 . The method of  claim 23 , wherein the phenotype specific nearest shrunken centroid comprises balancing about a 10-fold cross validation in a training set. 
   
   
       25 . A method of predicting a prognostic outcome for heart disease or recovery from heart failure comprising:
 identifying in a biological sample from a patient a composition comprising biomolecules: 232669_at (Hypoxia inducible factor 3, alpha subunit), 214951_at (solute carrier family 26, member 10), 243482_at (Epidermal growth factor receptor pathway substrate 15-like 1), 226210_s_at (maternally expressed 3), 232159_at (Epidermal growth factor receptor pathway substrate 15-like 1), 233026_s_at (PDZ domain containing), 211996_s_at (KIAA0220-like protein hypothetical gene LOC 283846), 243774_at (mucin 20, cell surface associated), 242551_at (Chromosome 18 open reading frame), 244548_at (Rho GTPase activating protein 26), 244208_at (Checkpoint suppressor 1), 239984_at (Sodium channel, voltage-gated, type VII, alpha), 230683_at (cDNA:FLJ20892 fis, clone ADKA03430), 214869_at (apolipoprotein L, 6), 241597_at (Arginine-glutamic acid dipeptide (RE) repeats), 235887_at (5 mg-6 homolog, nonsense mediated mRNA decay factor ( C. elegans )), 229957_at (transmembrane protein 91), 223546_x_at (LUC7L-like ( S. cerevisiae )), 239567_at (Rho GTPase activating protein 10), 242194_at (Cullin 4A), 1558525_at (hypothetical protein LOC283901), 227178_at (CUG triplet repeat, RNA binding protein 2), 228198_s_at (Mitochondrial ribosomal protein S9), 202379_s_at (natural killer-tumor recognition sequence), 224260_at (cDNA clone), 238643_at (Neuroblastoma, suppression of tumorigenicity 1), 232253_at (RAD50 homolog ( S. cerevisiae )), 227968_at (Parkinson disease 7 domain containing 1), 233197_at (kelch-like 9 ( Drosophila )), 244512_at (transcribed locus strongly similar to XP — 0010813421), 233443_at (hypothetical protein LOC389362), 231275_at (FLJ42875 protein), 226419_s_at (hypothetical protein LOC64546), 201221_s_at small nuclear ribonucleoprotein 70 kDa polypeptide), 209354_at (tumor necrosis factor receptor family member 14), 226571_s_at (protein tyrosine phosphatase receptor type, S), 220728_at (EST), 203071_at (sema domain, immunoglobulin domain (Ig), short basic domain), 213946_s_at obscurin-like 1, similar to titin isoform N2-B), 201394_s_at (RNA binding motif protein 5), 203748_x_at (RNA binding motif, single stranded interacting protein 1), 223147_s_at (WD repeat domain 33), 213773_x_at (NOL/NOP2/Sun domain family, member 5), 1560049_at CUG triplet repeat, RNA binding protein 2), 243974_at (cDNA clone IMAGE:4821815), 201510_at E74-like factor 3 (ets domain transcription factor, epithelial specific), complementary sequences, fragments, alleles, variants, derivatives and/or gene products thereof; and,   assessing the probability of identification of each component gene in each sample;   assigning each to a class; and,   predicting the prognostic outcome for heart disease or recovery from heart failure.   
   
   
       26 . The method of  claim 25 , wherein the gene sequences are over-expressed by at least about 20% as compared to a normal cell or normal subject. 
   
   
       27 . A method of identifying and distinguishing between patients at a high risk of heart disease and patients with a good prognosis for recovery comprising:
 identifying biomolecules comprising: 232669_at (Hypoxia inducible factor 3, alpha subunit), 214951_at (solute carrier family 26, member 10), 243482_at (Epidermal growth factor receptor pathway substrate 15-like 1), 226210_s_at (maternally expressed 3), 232159_at (Epidermal growth factor receptor pathway substrate 15-like 1), 233026_s_at (PDZ domain containing), 211996_s_at (KIAA0220-like protein hypothetical gene LOC 283846), 243774_at (mucin 20, cell surface associated), 242551_at (Chromosome 18 open reading frame), 244548_at (Rho GTPase activating protein 26), 244208_at (Checkpoint suppressor 1), 239984_at (Sodium channel, voltage-gated, type VII, alpha), 230683_at (cDNA:FLJ20892 fis, clone ADKA03430), 214869_at (apolipoprotein L, 6), 241597_at (Arginine-glutamic acid dipeptide (RE) repeats), 235887_at (5 mg-6 homolog, nonsense mediated mRNA decay factor ( C. elegans )), 229957_at (transmembrane protein 91), 223546_x_at (LUC7L-like ( S. cerevisiae )), 239567_at (Rho GTPase activating protein 10), 242194_at (Cullin 4A), 1558525_at (hypothetical protein LOC283901), 227178_at (CUG triplet repeat, RNA binding protein 2), 228198_s_at (Mitochondrial ribosomal protein S9), 202379_s_at (natural killer-tumor recognition sequence), 224260_at (cDNA clone), 238643_at (Neuroblastoma, suppression of tumorigenicity 1), 232253_at (RAD50 homolog ( S. cerevisiae )), 227968_at (Parkinson disease 7 domain containing 1), 233197_at (kelch-like 9 ( Drosophila )), 244512_at (transcribed locus strongly similar to XP — 0010813421), 233443_at (hypothetical protein LOC389362), 231275_at (FLJ42875 protein), 226419_s_at (hypothetical protein LOC64546), 201221_s_at small nuclear ribonucleoprotein 70 kDa polypeptide), 209354_at (tumor necrosis factor receptor family member 14), 226571_s_at (protein tyrosine phosphatase receptor type, S), 220728_at (EST), 203071_at (sema domain, immunoglobulin domain (Ig), short basic domain), 213946_s_at obscurin-like 1, similar to titin isoform N2-B), 201394_s_at (RNA binding motif protein 5), 203748_x_at (RNA binding motif, single stranded interacting protein 1), 223147_s_at (WD repeat domain 33), 213773_x_at (NOL/NOP2/Sun domain family, member 5), 1560049_at CUG triplet repeat, RNA binding protein 2), 243974_at (cDNA clone IMAGE:4821815), 201510_at E74-like factor 3 (ets domain transcription factor, epithelial specific), complementary sequences, fragments, alleles, variants, derivatives and/or gene products thereof;   assessing the probability of identification of each component gene in each sample;   assigning each to a class; and,   identifying and distinguishing between patients at a high risk of heart disease and patients with a good prognosis for recovery.   
   
   
       28 . A molecular composition comprising biomolecules: 1558458_at (Hypothetical LOC401320), 1560049_at (CUG triplet repeat, RNA binding protein 2, CUGBP2), 201394_s_at (RNA binding motif protein 5, RBM5), 201655_s_at (heparan sulfate proteoglycan 2 (perlecan), HSPG2), 202379_s_at (natural killer-tumor recognition sequence, NKTR), 202808_at, 203071_at (sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3B, SEMA3B), 203748_x_at (RNA binding motif, single stranded interacting protein 1, RBMS1), 203981_s_at (ATP-binding cassette, sub-family D (ALD), member 4, ABCD4), 204737_s_at (myosin, heavy chain 6, myosin, heavy chain 7, MYH6///MYH7), 204978_at (splicing factor, arginine/serine-rich 16, SFRS16), 206209_s_at (carbonic anhydrase IV, CA4), 207541_s_at (exosome component 10, EXOSC10), 207798_s_at (ataxin 2-like, ATXN2L), 208978_at (cysteine-rich protein 2, CRIP2), 209354_at (tumor necrosis factor receptor superfamily, member 14 TNFRSF14), 210628_x_at (latent transforming growth factor beta binding protein 4, LTBP4), 211909_x_at (prostaglandin E receptor 3 (subtype EP3), PTGER3), 211996_at (KIAA0220-like protein, nuclear pore complex (LOC23117), 212487_at (G patch domain containing 8, GPATCH8), 213946_s_at (obscurin-like 1, OBSL1), 214951_at (solute carrier family 26, member 10, SLC26A10), 220219_s_at (leucine rich repeat containing 37A, LRRC37A), 221071_at, 221780_s_at (DEAD (Asp-Glu-Ala-Asp) box polypeptide 27DDX27), 221806_s_at (SET domain containing 5, SETD5), 221833_at (Lon peptidase 2, peroxisomal, LONP2), 223546_x_at (LUC7-like ( S. cerevisiae ), LUC7L), 224260_at (cDNA clone IMAGE:4478733), 225562_at (AS p21 protein activator 3, RASA3), 226040_at (mRNA; cDNA DKFZp762N156 (from clone DKFZp762N156), 227968_at (Parkinson disease 7 domain containing 1, PDDC1), 228198_s_at (Mitochondrial ribosomal protein S9, MRPS9), 229830_at (Transcribed locus), 230683_at (cDNA: FLJ20892 fis, clone ADKA03430), 238185_at (RNA binding motif, single stranded interacting protein 1, RBMS1), 241597_at (Arginine-glutamic acid dipeptide (RE) repeats, RERE), 242551_at (Chromosome 18 open reading frame 1, C18orf1), 244208_at (Checkpoint suppressor 1, CHES1), 244494_at (Zinc finger, DHHC-type containing 1, ZDHHC1), and 244548_at (Rho GTPase activating protein 26, ARHGAP26) complementary sequences, fragments, alleles, variants, derivatives and/or gene products thereof. 
   
   
       29 . The molecular composition of  claim 28  wherein detection in a cell or patient of the biomolecules, complementary sequences, fragments, alleles, variants, derivatives and/or gene products thereof; is predictive of clinical diagnostic outcome and prognosis of heart failure. 
   
   
       30 . The molecular composition of  claim 28 , wherein the biomolecules, complementary sequences, fragments, alleles, variants, derivatives and/or gene products thereof, are modulated and/or over-expressed at levels by at least 1% to a 100% or more in a cell or patient as compared to levels in a normal cell or normal subject. 
   
   
       31 . The molecular composition of  claim 28 , wherein the biomolecules, complementary sequences, fragments, alleles, variants, derivatives and/or gene products thereof; are modulated and/or over-expressed by about 50% in a cell or a patient as compared to levels in a normal cell or normal subject. 
   
   
       32 . The molecular composition of  claim 28 , wherein the biomolecules, complementary sequences, fragments, alleles, variants, derivatives and/or gene products thereof; are modulated and/or over-expressed by about 75% in a cell or a patient as compared to levels in a normal cell or normal subject. 
   
   
       33 . The molecular composition of  claim 28 , wherein at least nine biomolecules are prognostic in individual risk assessment in a patient, predictive of clinical diagnostic outcome and prognosis of heart failure. 
   
   
       34 . The molecular composition of  claim 28 , wherein a plurality of biomolecules are prognostic in individual risk assessment in a patient for onset of heart failure. 
   
   
       35 . A biomarker (TBB) predictive of clinical diagnostic outcome and prognosis of heart failure, comprising nucleic acid sequences/biomolecules comprising: 1558458_at (Hypothetical LOC401320), 1560049_at (CUG triplet repeat, RNA binding protein 2, CUGBP2), 201394_s_at (RNA binding motif protein 5, RBM5), 201655_s_at (heparan sulfate proteoglycan 2 (perlecan), HSPG2), 202379_s_at (natural killer-tumor recognition sequence, NKTR), 202808_at, 203071_at (sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3B, SEMA3B), 203748_x_at (RNA binding motif, single stranded interacting protein 1, RBMS1), 203981_s_at (ATP-binding cassette, sub-family D (ALD), member 4, ABCD4), 204737_s_at (myosin, heavy chain 6, myosin, heavy chain 7, MYH6///MYH7), 204978_at (splicing factor, arginine/serine-rich 16, SFRS16), 206209_s_at (carbonic anhydrase IV, CA4), 207541_s_at (exosome component 10, EXOSC10), 207798_s_at (ataxin 2-like, ATXN2L), 208978_at (cysteine-rich protein 2, CRIP2), 209354_at (tumor necrosis factor receptor superfamily, member 14 TNFRSF14), 210628_x_at (latent transforming growth factor beta binding protein 4, LTBP4), 211909_x_at (prostaglandin E receptor 3 (subtype EP3), PTGER3), 211996_at (KIAA0220-like protein, nuclear pore complex (LOC23117), 212487_at (G patch domain containing 8, GPATCH8), 213946_s_at (obscurin-like 1, OBSL1), 214951_at (solute carrier family 26, member 10, SLC26A10), 220219_s_at (leucine rich repeat containing 37A, LRRC37A), 221071_at, 221780_s_at (DEAD (Asp-Glu-Ala-Asp) box polypeptide 27DDX27), 221806_s_at (SET domain containing 5, SETD5), 221833_at (Lon peptidase 2, peroxisomal, LONP2), 223546_x_at (LUC7-like ( S. cerevisiae ), LUC7L), 224260_at (cDNA clone IMAGE:4478733), 225562_at (AS p21 protein activator 3, RASA3), 226040_at (mRNA; cDNA DKFZp762N156 (from clone DKFZp762N156), 227968_at (Parkinson disease 7 domain containing 1, PDDC1), 228198_s_at (Mitochondrial ribosomal protein S9, MRPS9), 229830_at (Transcribed locus), 230683_at (cDNA: FLJ20892 fis, clone ADKA03430), 238185_at (RNA binding motif, single stranded interacting protein 1, RBMS1), 241597_at (Arginine-glutamic acid dipeptide (RE) repeats, RERE), 242551_at (Chromosome 18 open reading frame 1, C18orf1), 244208_at (Checkpoint suppressor 1, CHES1), 244494_at (Zinc finger, DHHC-type containing 1, ZDHHC1), and 244548_at (Rho GTPase activating protein 26, ARHGAP26) complementary sequences, fragments, alleles, variants, derivatives and/or gene products thereof. 
   
   
       36 . The biomarker of  claim 35 , wherein detection in a cell or patient of the biomolecules, complementary sequences, fragments, alleles, variants, derivatives and/or gene products thereof, predictive of clinical diagnostic outcome and prognosis of heart failure. 
   
   
       37 . The biomarker of  claim 35 , wherein the biomolecules, complementary sequences, fragments, alleles, variants, derivatives and/or gene products thereof, are modulated and/or over-expressed at levels by at least 1% to a 100% or more in a cell or patient as compared to levels in a normal cell or normal subject. 
   
   
       38 . The biomarker of  claim 35 , wherein the biomolecules, complementary sequences, fragments, alleles, variants, derivatives and/or gene products thereof, are modulated and/or over-expressed by about 50% in a cell or a patient as compared to levels in a normal cell or normal subject. 
   
   
       39 . The biomarker of  claim 35 , wherein the biomolecules, complementary sequences, fragments, alleles, variants, derivatives and/or gene products thereof, are modulated and/or over-expressed by about 75% in a cell or a patient as compared to levels in a normal cell or normal subject. 
   
   
       40 . An antibody or aptamer specific for each biomolecule comprising: 1558458_at (Hypothetical LOC401320), 1560049_at (CUG triplet repeat, RNA binding protein 2, CUGBP2), 201394_s_at (RNA binding motif protein 5, RBM5), 201655_s_at (heparan sulfate proteoglycan 2 (perlecan), HSPG2), 202379_s_at (natural killer-tumor recognition sequence, NKTR), 202808_at, 203071_at (sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3B, SEMA3B), 203748_x_at (RNA binding motif, single stranded interacting protein 1, RBMS1), 203981_s_at (ATP-binding cassette, sub-family D (ALD), member 4, ABCD4), 204737_s_at (myosin, heavy chain 6, myosin, heavy chain 7, MYH6///MYH7), 204978_at (splicing factor, arginine/serine-rich 16, SFRS16), 206209_s_at (carbonic anhydrase IV, CA4), 207541_s_at (exosome component 10, EXOSC10), 207798_s_at (ataxin 2-like, ATXN2L), 208978_at (cysteine-rich protein 2, CRIP2), 209354_at (tumor necrosis factor receptor superfamily, member 14 TNFRSF14), 210628_x_at (latent transforming growth factor beta binding protein 4, LTBP4), 211909_x_at (prostaglandin E receptor 3 (subtype EP3), PTGER3), 211996_at (KIAA0220-like protein, nuclear pore complex (LOC23117), 212487_at (G patch domain containing 8, GPATCH8), 213946_s_at (obscurin-like 1, OBSL1), 214951_at (solute carrier family 26, member 10, SLC26A10), 220219_s_at (leucine rich repeat containing 37A, LRRC37A), 221071_at, 221780_s_at (DEAD (Asp-Glu-Ala-Asp) box polypeptide 27DDX27), 221806_s_at (SET domain containing 5, SETD5), 221833_at (Lon peptidase 2, peroxisomal, LONP2), 223546_x_at (LUC7-like ( S. cerevisiae ), LUC7L), 224260_at (cDNA clone IMAGE:4478733), 225562_at (AS p21 protein activator 3, RASA3), 226040_at (mRNA; cDNA DKFZp762N156 (from clone DKFZp762N156), 227968_at (Parkinson disease 7 domain containing 1, PDDC1), 228198_s_at (Mitochondrial ribosomal protein S9, MRPS9), 229830_at (Transcribed locus), 230683_at (cDNA: FLJ20892 fis, clone ADKA03430), 238185_at (RNA binding motif, single stranded interacting protein 1, RBMS1), 241597_at (Arginine-glutamic acid dipeptide (RE) repeats, RERE), 242551_at (Chromosome 18 open reading frame 1, C18orf1), 244208_at (Checkpoint suppressor 1, CHES1), 244494_at (Zinc finger, DHHC-type containing 1, ZDHHC1), and 244548_at (Rho GTPase activating protein 26, ARHGAP26) complementary sequences, fragments, alleles, variants, derivatives and/or gene products thereof. 
   
   
       41 . A biochip comprising nucleic acid sequences: 1558458_at (Hypothetical LOC401320), 1560049_at (CUG triplet repeat, RNA binding protein 2, CUGBP2), 201394_s_at (RNA binding motif protein 5, RBM5), 201655_s_at (heparan sulfate proteoglycan 2 (perlecan), HSPG2), 202379_s_at (natural killer-tumor recognition sequence, NKTR), 202808_at, 203071_at (sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3B, SEMA3B), 203748_x_at (RNA binding motif, single stranded interacting protein 1, RBMS1), 203981_s_at (ATP-binding cassette, sub-family D (ALD), member 4, ABCD4), 204737_s_at (myosin, heavy chain 6, myosin, heavy chain 7, MYH6///MYH7), 204978_at (splicing factor, arginine/serine-rich 16, SFRS16), 206209_s_at (carbonic anhydrase IV, CA4), 207541_s_at (exosome component 10, EXOSC10), 207798_s_at (ataxin 2-like, ATXN2L), 208978_at (cysteine-rich protein 2, CRIP2), 209354_at (tumor necrosis factor receptor superfamily, member 14 TNFRSF14), 210628_x_at (latent transforming growth factor beta binding protein 4, LTBP4), 211909_x_at (prostaglandin E receptor 3 (subtype EP3), PTGER3), 211996_at (KIAA0220-like protein, nuclear pore complex (LOC23117), 212487_at (G patch domain containing 8, GPATCH8), 213946_s_at (obscurin-like 1, OBSL1), 214951_at (solute carrier family 26, member 10, SLC26A10), 220219_s_at (leucine rich repeat containing 37A, LRRC37A), 221071_at, 221780_s_at (DEAD (Asp-Glu-Ala-Asp) box polypeptide 27DDX27), 221806_s_at (SET domain containing 5, SETD5), 221833_at (Lon peptidase 2, peroxisomal, LONP2), 223546_x_at (LUC7-like ( S. cerevisiae ), LUC7L), 224260_at (cDNA clone IMAGE:4478733), 225562_at (AS p21 protein activator 3, RASA3), 226040_at (mRNA; cDNA DKFZp762N156 (from clone DKFZp762N156), 227968_at (Parkinson disease 7 domain containing 1, PDDC1), 228198_s_at (Mitochondrial ribosomal protein S9, MRPS9), 229830_at (Transcribed locus), 230683_at (cDNA: FLJ20892 fis, clone ADKA03430), 238185_at (RNA binding motif, single stranded interacting protein 1, RBMS1), 241597_at (Arginine-glutamic acid dipeptide (RE) repeats, RERE), 242551_at (Chromosome 18 open reading frame 1, C18orf1), 244208_at (Checkpoint suppressor 1, CHES1), 244494_at (Zinc finger, DHHC-type containing 1, ZDHHC1), and 244548_at (Rho GTPase activating protein 26, ARHGAP26) complementary sequences, fragments, alleles, variants, derivatives and/or gene products thereof. 
   
   
       42 . The biochip of  claim 41 , wherein the biochip comprises at least ten nucleic acid sequences, complementary sequences, fragments, alleles, variants, derivatives and/or gene products thereof. 
   
   
       43 . A method of assessing identifying and distinguishing between patients at a high risk of heart disease and patients with a good prognosis for recovery comprising:
 identifying in a biological sample from a patient a molecular signature comprising a transcriptomic based biomarker (TBB): 1558458_at (Hypothetical LOC401320), 1560049_at (CUG triplet repeat, RNA binding protein 2, CUGBP2), 201394_s_at (RNA binding motif protein 5, RBM5), 201655_s_at (heparan sulfate proteoglycan 2 (perlecan), HSPG2), 202379_s_at (natural killer-tumor recognition sequence, NKTR), 202808_at, 203071_at (sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3B, SEMA3B), 203748_x_at (RNA binding motif, single stranded interacting protein 1, RBMS1), 203981_s_at (ATP-binding cassette, sub-family D (ALD), member 4, ABCD4), 204737_s_at (myosin, heavy chain 6, myosin, heavy chain 7, MYH6///MYH7), 204978_at (splicing factor, arginine/serine-rich 16, SFRS16), 206209_s_at (carbonic anhydrase IV, CA4), 207541_s_at (exosome component 10, EXOSC10), 207798_s_at (ataxin 2-like, ATXN2L), 208978_at (cysteine-rich protein 2, CRIP2), 209354_at (tumor necrosis factor receptor superfamily, member 14 TNFRSF14), 210628_x_at (latent transforming growth factor beta binding protein 4, LTBP4), 211909_x_at (prostaglandin E receptor 3 (subtype EP3), PTGER3), 211996_at (KIAA0220-like protein, nuclear pore complex (LOC23117), 212487_at (G patch domain containing 8, GPATCH8), 213946_s_at (obscurin-like 1, OBSL1), 214951_at (solute carrier family 26, member 10, SLC26A10), 220219_s_at (leucine rich repeat containing 37A, LRRC37A), 221071_at, 221780_s_at (DEAD (Asp-Glu-Ala-Asp) box polypeptide 27DDX27), 221806_s_at (SET domain containing 5, SETD5), 221833_at (Lon peptidase 2, peroxisomal, LONP2), 223546_x_at (LUC7-like ( S. cerevisiae ), LUC7L), 224260_at (cDNA clone IMAGE:4478733), 225562_at (AS p21 protein activator 3, RASA3), 226040_at (mRNA; cDNA DKFZp762N156 (from clone DKFZp762N156), 227968_at (Parkinson disease 7 domain containing 1, PDDC1), 228198_s_at (Mitochondrial ribosomal protein S9, MRPS9), 229830_at (Transcribed locus), 230683_at (cDNA: FLJ20892 fis, clone ADKA03430), 238185_at (RNA binding motif, single stranded interacting protein 1, RBMS1), 241597_at (Arginine-glutamic acid dipeptide (RE) repeats, RERE), 242551_at (Chromosome 18 open reading frame 1, C18orf1), 244208_at (Checkpoint suppressor 1, CHES1), 244494_at (Zinc finger, DHHC-type containing 1, ZDHHC1), and 244548_at (Rho GTPase activating protein 26, ARHGAP26) complementary sequences, fragments, alleles, variants, derivatives and/or gene products thereof;   assessing the probability of identification of each component gene in each sample;   assigning each to a class; and,   differentiating between idiopathic cardiomyopathy and myocarditis.   
   
   
       44 . The method of  claim 43 , wherein the biomarker is identified from a patient by isolating nucleic acids obtained from a biological sample. 
   
   
       45 . The method of  claim 43 , wherein the nucleic acids are hybridized to the biochip and raw intensity values from microarray hybridization are normalized and phenotype specific differences in gene expression are identified. 
   
   
       46 . The method of  claim 45 , wherein the differences in gene expression are identified by significance analysis of microarrays, wherein significance is defined with a q-value and multiple comparisons comprise an adjusted p-value. 
   
   
       47 . The method of  claim 45 , wherein the phenotype specificity is identified by creating a classifier in a training set comprising about 66% of data obtained, with subsequent validation in a test set comprising about 33% of data obtained and defining a phenotype specific nearest shrunken centroid for classification. 
   
   
       48 . The method of  claim 45 , wherein the phenotype specific nearest shrunken centroid comprises balancing about a 10-fold cross validation in a training set. 
   
   
       49 . A method of predicting a prognostic outcome for heart disease or recovery from heart failure comprising:
 identifying in a biological sample from a patient a composition comprising biomolecules: 1558458_at (Hypothetical LOC401320), 1560049_at (CUG triplet repeat, RNA binding protein 2, CUGBP2), 201394_s_at (RNA binding motif protein 5, RBM5), 201655_s_at (heparan sulfate proteoglycan 2 (perlecan), HSPG2), 202379_s_at (natural killer-tumor recognition sequence, NKTR), 202808_at, 203071_at (sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3B, SEMA3B), 203748_x_at (RNA binding motif, single stranded interacting protein 1, RBMS1), 203981_s_at (ATP-binding cassette, sub-family D (ALD), member 4, ABCD4), 204737_s_at (myosin, heavy chain 6, myosin, heavy chain 7, MYH6///MYH7), 204978_at (splicing factor, arginine/serine-rich 16, SFRS16), 206209_s_at (carbonic anhydrase IV, CA4), 207541_s_at (exosome component 10, EXOSC10), 207798_s_at (ataxin 2-like, ATXN2L), 208978_at (cysteine-rich protein 2, CRIP2), 209354_at (tumor necrosis factor receptor superfamily, member 14 TNFRSF14), 210628_x_at (latent transforming growth factor beta binding protein 4, LTBP4), 211909_x_at (prostaglandin E receptor 3 (subtype EP3), PTGER3), 211996_at (KIAA0220-like protein, nuclear pore complex (LOC23117), 212487_at (G patch domain containing 8, GPATCH8), 213946_s_at (obscurin-like 1, OBSL1), 214951_at (solute carrier family 26, member 10, SLC26A10), 220219_s_at (leucine rich repeat containing 37A, LRRC37A), 221071_at, 221780_s_at (DEAD (Asp-Glu-Ala-Asp) box polypeptide 27DDX27), 221806_s_at (SET domain containing 5, SETD5), 221833_at (Lon peptidase 2, peroxisomal, LONP2), 223546_x_at (LUC7-like ( S. cerevisiae ), LUC7L), 224260_at (cDNA clone IMAGE:4478733), 225562_at (AS p21 protein activator 3, RASA3), 226040_at (mRNA; cDNA DKFZp762N156 (from clone DKFZp762N156), 227968_at (Parkinson disease 7 domain containing 1, PDDC1), 228198_s_at (Mitochondrial ribosomal protein S9, MRPS9), 229830_at (Transcribed locus), 230683_at (cDNA: FLJ20892 fis; clone ADKA03430), 238185_at (RNA binding motif, single stranded interacting protein 1, RBMS1), 241597_at (Arginine-glutamic acid dipeptide (RE) repeats, RERE), 242551_at (Chromosome 18 open reading frame 1, C18orf1), 244208_at (Checkpoint suppressor 1, CHES1), 244494_at (Zinc finger, DHHC-type containing 1, ZDHHC1), and 244548_at (Rho GTPase activating protein 26, ARHGAP26), complementary sequences, fragments, alleles, variants, derivatives and/or gene products thereof; and,   assessing the probability of identification of each component molecule in each sample;   assigning each to a class; and,   predicting heart disease or cardiomyopathy.   
   
   
       50 . The method of  claim 49 , wherein the biomolecules are modulated and/or over-expressed by at least about 20% as compared to a normal cell or normal subject. 
   
   
       51 . A method of identifying and distinguishing between patients at a high risk of heart disease and patients with a good prognosis for recovery comprising:
 identifying biomolecules comprising: 1558458_at (Hypothetical LOC401320), 1560049_at (CUG triplet repeat, RNA binding protein 2, CUGBP2), 201394_s_at (RNA binding motif protein 5, RBM5), 201655_s_at (heparan sulfate proteoglycan 2 (perlecan), HSPG2), 202379_s_at (natural killer-tumor recognition sequence, NKTR), 202808_at, 203071_at (sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3B, SEMA3B), 203748_x_at (RNA binding motif, single stranded interacting protein 1, RBMS1), 203981_s_at (ATP-binding cassette, sub-family D (ALD), member 4, ABCD4), 204737_s_at (myosin, heavy chain 6, myosin, heavy chain 7, MYH6///MYH7), 204978_at (splicing factor, arginine/serine-rich 16, SFRS16), 206209_s_at (carbonic anhydrase IV, CA4), 207541_s_at (exosome component 10, EXOSC10), 207798_s_at (ataxin 2-like, ATXN2L), 208978_at (cysteine-rich protein 2, CRIP2), 209354_at (tumor necrosis factor receptor superfamily, member 14 TNFRSF14), 210628_x_at (latent transforming growth factor beta binding protein 4, LTBP4), 211909_x_at (prostaglandin E receptor 3 (subtype EP3), PTGER3), 211996_at (KIAA0220-like protein, nuclear pore complex (LOC23117), 212487_at (G patch domain containing 8, GPATCH8), 213946_s_at (obscurin-like 1, OBSL1), 214951_at (solute carrier family 26, member 10, SLC26A10), 220219_s_at (leucine rich repeat containing 37A, LRRC37A), 221071_at, 221780_s_at (DEAD (Asp-Glu-Ala-Asp) box polypeptide 27DDX27), 221806_s_at (SET domain containing 5, SETD5), 221833_at (Lon peptidase 2, peroxisomal, LONP2), 223546_x_at (LUC7-like ( S. cerevisiae ), LUC7L), 224260_at (cDNA clone IMAGE:4478733), 225562_at (AS p21 protein activator 3, RASA3), 226040_at (mRNA; cDNA DKFZp762N156 (from clone DKFZp762N156), 227968_at (Parkinson disease 7 domain containing 1, PDDC1), 228198_s_at (Mitochondrial ribosomal protein S9, MRPS9), 229830_at (Transcribed locus), 230683_at (cDNA: FLJ20892 fis, clone ADKA03430), 238185_at (RNA binding motif, single stranded interacting protein 1, RBMS1), 241597_at (Arginine-glutamic acid dipeptide (RE) repeats, RERE), 242551_at (Chromosome 18 open reading frame 1, C18orf1), 244208_at (Checkpoint suppressor 1, CHES1), 244494_at (Zinc finger, DHHC-type containing 1, ZDHHC1), and 244548_at (Rho GTPase activating protein 26, ARHGAP26) complementary sequences, fragments, alleles, variants, derivatives and/or gene products thereof;   assessing the probability of identification of each component biomoelcule in each sample;   assigning each to a class; and,   identifying and distinguishing between patients at a high risk of heart disease and patients with a good prognosis for recovery.   
   
   
       52 . A cell expressing any one or more of nucleic acid sequences or products thereof: 232669_at (Hypoxia inducible factor 3, alpha subunit), 214951_at (solute carrier family 26, member 10), 243482_at (Epidermal growth factor receptor pathway substrate 15-like 1), 226210_s_at (maternally expressed 3), 232159_at (Epidermal growth factor receptor pathway substrate 15-like 1), 233026_s_at (PDZ domain containing), 211996_s_at (KIAA0220-like protein hypothetical gene LOC 283846), 243774_at (mucin 20, cell surface associated), 242551_at (Chromosome 18 open reading frame), 244548_at (Rho GTPase activating protein 26), 244208_at (Checkpoint suppressor 1), 239984_at (Sodium channel, voltage-gated, type VII, alpha), 230683_at (cDNA:FLJ20892 fis, clone ADKA03430), 214869_at (apolipoprotein L, 6), 241597_at (Arginine-glutamic acid dipeptide (RE) repeats), 235887_at (5 mg-6 homolog, nonsense mediated mRNA decay factor ( C. elegans )), 229957_at (transmembrane protein 91), 223546_x_at (LUC7L-like ( S. cerevisiae )), 239567_at (Rho GTPase activating protein 10), 242194_at (Cullin 4A), 1558525_at (hypothetical protein LOC283901), 227178_at (CUG triplet repeat, RNA binding protein 2), 228198_s_at (Mitochondrial ribosomal protein S9), 202379_s_at (natural killer-tumor recognition sequence), 224260_at (cDNA clone), 238643_at (Neuroblastoma, suppression of tumorigenicity 1), 232253_at (RAD50 homolog ( S. cerevisiae )), 227968_at (Parkinson disease 7 domain containing 1), 233197_at (kelch-like 9 ( Drosophila )), 244512_at (transcribed locus strongly similar to XP — 0010813421), 233443_at (hypothetical protein LOC389362), 231275_at (FLJ42875 protein), 226419_s_at (hypothetical protein LOC64546), 201221_s_at small nuclear ribonucleoprotein 70 kDa polypeptide), 209354_at (tumor necrosis factor receptor family member 14), 226571_s_at (protein tyrosine phosphatase receptor type, S), 220728_at (EST), 203071_at (sema domain, immunoglobulin domain (Ig), short basic domain), 213946_s_at obscurin-like 1, similar to titin isoform N2-B), 201394_s_at (RNA binding motif protein 5), 203748_x_at (RNA binding motif, single stranded interacting protein 1), 223147_s_at (WD repeat domain 33), 213773_x_at (NOL/NOP2/Sun domain family, member 5), 1560049_at CUG triplet repeat, RNA binding protein 2), 243974_at (cDNA clone IMAGE:4821815), 201510_at E74-like factor 3 (ets domain transcription factor, epithelial specific). 
   
   
       53 . A vector expressing any one or more nucleic acid products comprising: 232669_at (Hypoxia inducible factor 3, alpha subunit), 214951_at (solute carrier family 26, member 10), 243482_at (Epidermal growth factor receptor pathway substrate 15-like 1), 226210_s_at (maternally expressed 3), 232159_at (Epidermal growth factor receptor pathway substrate 15-like 1), 233026_s_at (PDZ domain containing), 211996_s_at (KIAA0220-like protein hypothetical gene LOC 283846), 243774_at (mucin 20, cell surface associated), 242551_at (Chromosome 18 open reading frame), 244548_at (Rho GTPase activating protein 26), 244208_at (Checkpoint suppressor 1), 239984_at (Sodium channel, voltage-gated, type VII, alpha), 230683_at (cDNA:FLJ20892 fis, clone ADKA03430), 214869_at (apolipoprotein L, 6), 241597_at (Arginine-glutamic acid dipeptide (RE) repeats), 235887_at (5 mg-6 homolog, nonsense mediated mRNA decay factor ( C. elegans )), 229957_at (transmembrane protein 91), 223546_x_at (LUC7L-like ( S. cerevisiae )), 239567_at (Rho GTPase activating protein 10), 242194_at (Cullin 4A), 1558525_at (hypothetical protein LOC283901), 227178_at (CUG triplet repeat, RNA binding protein 2), 228198_s_at (Mitochondrial ribosomal protein S9), 202379_s_at (natural killer-tumor recognition sequence), 224260_at (cDNA clone), 238643_at (Neuroblastoma, suppression of tumorigenicity 1), 232253_at (RAD50 homolog ( S. cerevisiae )), 227968_at (Parkinson disease 7 domain containing 1), 233197_at (kelch-like 9 ( Drosophila )), 244512_at (transcribed locus strongly similar to XP — 0010813421), 233443_at (hypothetical protein LOC389362), 231275_at (FLJ42875 protein), 226419_s_at (hypothetical protein LOC64546), 201221_s_at small nuclear ribonucleoprotein 70 kDa polypeptide), 209354_at (tumor necrosis factor receptor family member 14), 226571_s_at (protein tyrosine phosphatase receptor type, S), 220728_at (EST), 203071_at (sema domain, immunoglobulin domain (Ig), short basic domain), 213946_s_at obscurin-like 1, similar to titin isoform N2-B), 201394_s_at (RNA binding motif protein 5), 203748_x_at (RNA binding motif, single stranded interacting protein 1), 223147_s_at (WD repeat domain 33), 213773_x_at (NOL/NOP2/Sun domain family, member 5), 1560049_at CUG triplet repeat, RNA binding protein 2), 243974_at (cDNA clone IMAGE:4821815), 201510_at E74-like factor 3 (ets domain transcription factor, epithelial specific) complementary sequences, fragments, alleles, variants, derivatives and/or gene products thereof. 
   
   
       54 . A cell expressing any one or more of nucleic acid sequences or products thereof comprising: 1558458_at (Hypothetical LOC401320), 1560049_at (CUG triplet repeat, RNA binding protein 2, CUGBP2), 201394_s_at (RNA binding motif protein 5, RBM5), 201655_s_at (heparan sulfate proteoglycan 2 (perlecan), HSPG2), 202379_s_at (natural killer-tumor recognition sequence, NKTR), 202808_at, 203071_at (sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3B, SEMA3B), 203748_x_at (RNA binding motif, single stranded interacting protein 1, RBMS1), 203981_s_at (ATP-binding cassette, sub-family D (ALD), member 4, ABCD4), 204737_s_at (myosin, heavy chain 6, myosin, heavy chain 7, MYH6///MYH7), 204978_at (splicing factor, arginine/serine-rich 16, SFRS16), 206209_s_at (carbonic anhydrase IV, CA4), 207541_s_at (exosome component 10, EXOSC10), 207798_s_at (ataxin 2-like, ATXN2L), 208978_at (cysteine-rich protein 2, CRIP2), 209354_at (tumor necrosis factor receptor superfamily, member 14 TNFRSF14), 210628_x_at (latent transforming growth factor beta binding protein 4, LTBP4), 211909_x_at (prostaglandin E receptor 3 (subtype EP3), PTGER3), 211996_at (KIAA0220-like protein, nuclear pore complex (LOC23117), 212487_at (G patch domain containing 8, GPATCH8), 213946_s_at (obscurin-like 1, OBSL1), 214951_at (solute carrier family 26, member 10, SLC26A10), 220219_s_at (leucine rich repeat containing 37A, LRRC37A), 221071_at, 221780_s_at (DEAD (Asp-Glu-Ala-Asp) box polypeptide 27DDX27), 221806_s_at (SET domain containing 5, SETD5), 221833_at (Lon peptidase 2, peroxisomal, LONP2), 223546_x_at (LUC7-like ( S. cerevisiae ), LUC7L), 224260_at (cDNA clone IMAGE:4478733), 225562_at (AS p21 protein activator 3, RASA3), 226040_at (mRNA; cDNA DKFZp762N156 (from clone DKFZp762N156), 227968_at (Parkinson disease 7 domain containing 1, PDDC1), 228198_s_at (Mitochondrial ribosomal protein S9, MRPS9), 229830_at (Transcribed locus), 230683_at (cDNA: FLJ20892 fis, clone ADKA03430), 238185_at (RNA binding motif, single stranded interacting protein 1, RBMS1), 241597_at (Arginine-glutamic acid dipeptide (RE) repeats, RERE), 242551_at (Chromosome 18 open reading frame 1, C18orf1), 244208_at (Checkpoint suppressor 1, CHES1), 244494_at (Zinc finger, DHHC-type containing 1, ZDHHC1), and 244548_at (Rho GTPase activating protein 26, ARHGAP26) complementary sequences, fragments, alleles, variants, derivatives and/or gene products thereof. 
   
   
       55 . A vector expressing any one or more of nucleic acid sequences comprising: 1558458_at (Hypothetical LOC401320), 1560049_at (CUG triplet repeat, RNA binding protein 2, CUGBP2), 201394_s_at (RNA binding motif protein 5, RBM5), 201655_s_at (heparan sulfate proteoglycan 2 (perlecan), HSPG2), 202379_s_at (natural killer-tumor recognition sequence, NKTR), 202808_at, 203071_at (sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3B, SEMA3B), 203748_x_at (RNA binding motif, single stranded interacting protein 1, RBMS1), 203981_s_at (ATP-binding cassette, sub-family D (ALD), member 4, ABCD4), 204737_s_at (myosin, heavy chain 6, myosin, heavy chain 7, MYH6///MYH7), 204978_at (splicing factor, arginine/serine-rich 16, SFRS16), 206209_s_at (carbonic anhydrase IV, CA4), 207541_s_at (exosome component 10, EXOSC10), 207798_s_at (ataxin 2-like, ATXN2L), 208978_at (cysteine-rich protein 2, CRIP2), 209354_at (tumor necrosis factor receptor superfamily, member 14 TNFRSF14), 210628_x_at (latent transforming growth factor beta binding protein 4, LTBP4), 211909_x_at (prostaglandin E receptor 3 (subtype EP3), PTGER3), 211996_at (KIAA0220-like protein, nuclear pore complex (LOC23117), 212487_at (G patch domain containing 8, GPATCH8), 213946_s_at (obscurin-like 1, OBSL1), 214951_at (solute carrier family 26, member 10, SLC26A10), 220219_s_at (leucine rich repeat containing 37A, LRRC37A), 221071_at, 221780_s_at (DEAD (Asp-Glu-Ala-Asp) box polypeptide 27DDX27), 221806_s_at (SET domain containing 5, SETD5), 221833_at (Lon peptidase 2, peroxisomal, LONP2), 223546_x_at (LUC7-like ( S. cerevisiae ), LUC7L), 224260_at (cDNA clone IMAGE:4478733), 225562_at (AS p21 protein activator 3, RASA3), 226040_at (mRNA; cDNA DKFZp762N156 (from clone DKFZp762N156), 227968_at (Parkinson disease 7 domain containing 1, PDDC1), 228198_s_at (Mitochondrial ribosomal protein S9, MRPS9), 229830_at (Transcribed locus), 230683_at (cDNA: FLJ20892 fis, clone ADKA03430), 238185_at (RNA binding motif, single stranded interacting protein 1, RBMS1), 241597_at (Arginine-glutamic acid dipeptide (RE) repeats, RERE), 242551_at (Chromosome 18 open reading frame 1, C18orf1), 244208_at (Checkpoint suppressor 1, CHES1), 244494_at (Zinc finger, DHHC-type containing 1, ZDHHC1), and 244548_at (Rho GTPase activating protein 26, ARHGAP26) complementary sequences, fragments, alleles, variants, derivatives and/or gene products thereof.